These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 12932387)
1. Imatinib for systemic mast-cell disease. Pardanani A; Elliott M; Reeder T; Li CY; Baxter EJ; Cross NC; Tefferi A Lancet; 2003 Aug; 362(9383):535-6. PubMed ID: 12932387 [TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Droogendijk HJ; Kluin-Nelemans HJ; van Doormaal JJ; Oranje AP; van de Loosdrecht AA; van Daele PL Cancer; 2006 Jul; 107(2):345-51. PubMed ID: 16779792 [TBL] [Abstract][Full Text] [Related]
3. The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107. von Bubnoff N; Gorantla SH; Kancha RK; Lordick F; Peschel C; Duyster J Leukemia; 2005 Sep; 19(9):1670-1. PubMed ID: 16015383 [No Abstract] [Full Text] [Related]
4. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Vega-Ruiz A; Cortes JE; Sever M; Manshouri T; Quintás-Cardama A; Luthra R; Kantarjian HM; Verstovsek S Leuk Res; 2009 Nov; 33(11):1481-4. PubMed ID: 19193436 [TBL] [Abstract][Full Text] [Related]
5. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Akin C; Fumo G; Yavuz AS; Lipsky PE; Neckers L; Metcalfe DD Blood; 2004 Apr; 103(8):3222-5. PubMed ID: 15070706 [TBL] [Abstract][Full Text] [Related]
6. Successful treatment of KIT D816V-positive, imatinib-resistant systemic mastocytosis with interferon-alpha. Yoshida C; Takeuchi M; Tsuchiyama J; Sadahira Y Intern Med; 2009; 48(22):1973-8. PubMed ID: 19915299 [TBL] [Abstract][Full Text] [Related]
7. [Systemic mastocytosis without the typical mutation of codon 816 successfully treated with imatinib]. Hirayama Y; Konuma Y; Kohda K; Ando M; Obata M; Ueno Y; Sasagawa Y; Wada Y; Shirao S Nihon Naika Gakkai Zasshi; 2008 Oct; 97(10):2542-5. PubMed ID: 19051746 [No Abstract] [Full Text] [Related]
8. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate. Isotani M; Tamura K; Yagihara H; Hikosaka M; Ono K; Washizu T; Bonkobara M Vet Immunol Immunopathol; 2006 Nov; 114(1-2):168-72. PubMed ID: 16908071 [TBL] [Abstract][Full Text] [Related]
9. Role of imatinib in the treatment of pediatric onset indolent systemic mastocytosis: a case report. Agarwala MK; George R; Mathews V; Balasubramanian P; Thomas M; Nair S J Dermatolog Treat; 2013 Dec; 24(6):481-3. PubMed ID: 23659595 [TBL] [Abstract][Full Text] [Related]
12. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Ustun C; DeRemer DL; Akin C Leuk Res; 2011 Sep; 35(9):1143-52. PubMed ID: 21641642 [TBL] [Abstract][Full Text] [Related]
13. Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. Verstovsek S; Akin C; Manshouri T; Quintás-Cardama A; Huynh L; Manley P; Tefferi A; Cortes J; Giles FJ; Kantarjian H Leuk Res; 2006 Nov; 30(11):1365-70. PubMed ID: 16797704 [TBL] [Abstract][Full Text] [Related]
14. Canine intestinal mast cell tumor with c-kit exon 8 mutation responsive to imatinib therapy. Kobayashi M; Sugisaki O; Ishii N; Yamada O; Ito K; Kuroki S; Sasaki Y; Ono K; Washizu T; Bonkobara M Vet J; 2012 Jul; 193(1):264-7. PubMed ID: 22153896 [TBL] [Abstract][Full Text] [Related]
15. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Shah NP; Lee FY; Luo R; Jiang Y; Donker M; Akin C Blood; 2006 Jul; 108(1):286-91. PubMed ID: 16434489 [TBL] [Abstract][Full Text] [Related]
16. First case of an AIDS patient with systemic mast cell disease associated with FIP1-positive eosinophilia treated with imatinib mesylate therapy. Merante S; Chichino G; Boveri E; Gottardi E; Soverini S; Cilloni D; Martinelli G J Clin Oncol; 2006 Feb; 24(4):e6-7. PubMed ID: 16446324 [No Abstract] [Full Text] [Related]
17. Systemic mastocytosis: current classification and novel therapeutic options. Barbie DA; Deangelo DJ Clin Adv Hematol Oncol; 2006 Oct; 4(10):768-75. PubMed ID: 17099633 [TBL] [Abstract][Full Text] [Related]
18. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Lim KH; Pardanani A; Butterfield JH; Li CY; Tefferi A Am J Hematol; 2009 Dec; 84(12):790-4. PubMed ID: 19890907 [TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. Böhm A; Sonneck K; Gleixner KV; Schuch K; Pickl WF; Blatt K; Peter B; Herrmann H; Schernthaner GH; Pehamberger H; Rabitsch W; Sperr WR; Valent P Exp Hematol; 2010 Sep; 38(9):744-55. PubMed ID: 20553795 [TBL] [Abstract][Full Text] [Related]
20. Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412. de Melo Campos P; Machado-Neto JA; Scopim-Ribeiro R; Visconte V; Tabarroki A; Duarte AS; Barra FF; Vassalo J; Rogers HJ; Lorand-Metze I; Tiu RV; Costa FF; Olalla Saad ST; Traina F Leuk Res; 2014 Oct; 38(10):1245-51. PubMed ID: 25139846 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]